New hope for Hard-to-Treat thyroid cancer: experimental drug shows promise
NCT ID NCT05745363
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested an experimental drug called AL2846 in 33 people with a type of thyroid cancer that no longer responds to standard treatments. The goal was to see if the drug could shrink tumors or slow the cancer's growth. Participants took the drug by mouth, and doctors monitored their response and any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital Of Guilin Medical University
Guilin, Guangxi, 541001, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, 330029, China
-
Yunnan Cancer Hospital
Kunming, Yunnan, 650011, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could drug holidays improve thyroid cancer treatment?
- Radiation safety study aims to personalize thyroid cancer treatment
- Which neck surgery hurts least? new study aims to find out
- New scoring system could rate robot thyroid surgeons
- Radioactive iodine: unnecessary for some thyroid cancer patients?
- New model aims to predict tough thyroid surgeries before they start